Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients are increasingly being treated with multiple regimens. However, outcome after each line remains poorly characterized in the modern era. To address this knowledge gap, we retrospectively studied 404 consecutive...

Full description

Saved in:

Bibliographic Details
Published in:	Blood cancer journal (New York) 2019-05, Vol.9 (6), p.50-50, Article 50
Main Authors:	Kumar, Anita, Sha, Fushen, Toure, Ahmed, Dogan, Ahmet, Ni, Andy, Batlevi, Connie L, Palomba, Maria Lia M, Portlock, Carol, Straus, David J, Noy, Ariela, Horwitz, Steven M, Moskowitz, Alison, Hamlin, Paul, Moskowitz, Craig H, Matasar, Matthew J, Zelenetz, Andrew D, Younes, Anas
Format:	Article
Language:	eng
Subjects:	Adult Aged Aged, 80 and over Combined Modality Therapy Female Humans Kaplan-Meier Estimate Lymphoma Lymphoma, Mantle-Cell - diagnosis Lymphoma, Mantle-Cell - epidemiology Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - therapy Male Middle Aged Neoplasm Staging Prognosis Recurrence Retreatment Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients are increasingly being treated with multiple regimens. However, outcome after each line remains poorly characterized in the modern era. To address this knowledge gap, we retrospectively studied 404 consecutive MCL patients who were managed between 2000 and 2014 at Memorial Sloan Kettering Cancer Center. Histologic diagnosis was centrally confirmed, and patients were followed longitudinally from diagnosis throughout their disease course. Progression-free survival (PFS) and overall survival (OS) were determined by Kaplan-Meier method. The median OS and PFS after first-line treatment were 9.7 and 4.0 years, respectively. After second-line therapy, the median OS and PFS were 41.1 and 14.0 months, third line were 25.2 and 6.5 months, and fourth line were 14.4 and 5.0 months. In patients less than 65 years, stem cell transplant (SCT)-based frontline regimens were associated with improved PFS compared with non-SCT regimens (median PFS: 86.2 versus 40.0 months; P
ISSN:	2044-5385 2044-5385